Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. III. Pharmacological evaluations and molecular modeling studies of optically active 4,5,6,7-tetrahydro-1H-benzimidazole derivatives

Chemical and Pharmaceutical Bulletin

Volumn 44, Issue 9, 1996, Pages 1707-1716

  Ohta, Mitsuaki ^a   Suzuki, Takeshi ^a   Furuya, Toshio ^a   Kurihara, Hiroyuki ^a   Tokunaga, Tatsuhiro ^a   Miyata, Keiji ^a   Yanagisawa, Isao ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

5 hydroxytryptamine receptor antagonist; optical resolution; three dimensional molecular modeling; YM060 (ramosetron); YM114 (KAE 393)

Indexed keywords

3 (5 METHYL 1H IMIDAZOL 4 YL) 1 (1 METHYL 1H INDOL 3 YL) 1 PROPANONE; 4,5,6,7 TETRAHYDRO 5 (1 INDOLYLCARBONYL)BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; CISPLATIN; GRANISETRON; ONDANSETRON; RAMOSETRON; SEROTONIN; SEROTONIN 3 ANTAGONIST; ZACOPRIDE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIEMETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG POTENCY; ENANTIOMER; FERRET; GUINEA PIG; INTESTINE MOTILITY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; IRRITABLE COLON; MALE; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; RACEMIC MIXTURE; RAT; STRUCTURE ACTIVITY RELATION; VOMITING;

EID: 0029847888     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.44.1707     Document Type: Article

References (25)

1. a) part 1,Ohta M., Suzuki T., Koide T., Matsuhisa A., Furuya T., Miyata K., Yanagisawa I., Chem. Pharm. Bull., 44,991-999 (1996);
2. b) part 2, Ohta M., Suzuki T., Ohmori J., Koide T., Matsuhisa A., Furuya T., Miyata K., Yanagisawa I, ibid., 44,999-1008 (1996).
3. a) Sanger G. J., King F. D., Drug Design and Delivery. 3, 273-295 (1988);
4. b) King F. D., Sanger G. J., Drugs Future, 14, 875-889 (1989);
5. c) Kilpatrick G. J., Bunce K. T., Tyers M. B., Med. Res. Rev., 10, 441-475 (1990).
6. Butler A., Hill J. M., Ireland S. J., Jordan C. C., Tyers M. B.. Br. J. Pharmacol., 94 (Suppl.), 397-412 (1988).
7. Sanger G. J., Nelson D. R., Eur. J. Pharmacol., 159, 113-124 (1989).
8. a) Schmidt A. W., Peroutka S. J., Molecular Pharmacology, 36, 505-511 (1989);
9. b) Hibert M. F., Hoffmann R., Miller R. C., Carr A. A., J. Med. Chem., 33, 1594-1600 (1990);
10. c) Evans S. M., Galdes A., Gallm M., Pharmacol. Biochem. Behav., 40, 1033-1040 (1991).
11. Fozard J. R., Host M., Br. J. Pharmacol., 77, 520 (1982);
12. a) Miyata K., Kamato T., Nishida A., Ito H., Katsuyama Y., Iwai A., Yuki H., Yamano M., Tsutsumi R., Ohta M., Takeda M., Honda K., J. Pharmacol. Exp. Ther., 259, 15-21 (1991);
13. b) Kamato T., Ito H., Suzuki T.,Miyata K., Honda K., Jpn. J. Pharmacol., 67, 185-194 (1995).
14. Kilpatrick G. J., Jones B. J., Tyers M. B., Nature (London), 330, 746-748 (1987).
15. Hoyer D., Neijt H., Molecular Pharmacology, 33, 303-309 (1988).
16. Ito H., Akuzawa S., Tsutsumi R., Kiso T., Kamato T., Nishida A., Yamano M., Miyata K., Neuropharmacol., 34, 631-637 (1995).
17. SYBYL molecular modeling software, Tripos Inc., St. Louis, MO, U.S.A.
18. Pinkus L. M., Sarbin N. S., Gordon J. C., Munso H. R. Jr., Eur. J. Pharmacol., 179, 231-235 (1990).
19. Butler A., Hill J.M., Ireland S.J., Jordan C.C., Tyers M.B., Br. J. Pharmacol., 94, 397-412 (1988).
20. Kamato T., Miyata K., Ito H., Yuki H., Yamano M., Honda K., Jpn. J. Pharmacol., 57, 387-395 (1991).
21. Miyata K., Kamato T., Nishida A., Ito H., Yuki H., Yamano M., Tsutsumi R., Katsuyama Y., Honda K., J. Pharmacol. Exp. Ther., 261, 297-303 (1992).
22. Yamano M., Kamato T., Nishida A., Ito H., Yuki H., Tsutsumi R., Honda K., Miyata K., Jpn. J. Pharmacol., 65, 241-248 (1994).
23. Sheldrick G. H., "SHELXS86. Program for Crystal Structure Solution," University of Gottingen; Federal Republic of Germany, 1986.
24. International Tables for X-Ray Crystallography, Vol. IV, Kynoch, Birmingham, 1974, pp. 71-103.
25. Kindly provided by Dr. H. Higashida, Kanazawa University, Kanazawa, Japan.